Symtomax Group was established in 2017 with a commitment to advancing alternative and effective products to improve the health and well-being of people.
Mission: The company’s mission is to provide safe and effective high grade medical cannabis available to everyone who needs it and to offer alternative health care solutions in order to support and ease the healing process.
The team of professionals has decades of combined experience in cannabis cultivation, adhering to strict procedural and environmental protocols to maximize purity, quality and consistency.
Symtomax success is strengthened by its close working relationships with some of the cannabis industry’s largest cannabis-infused product manufacturers, pharmaceutical companies and growers.
Europe’s cannabis and cannabidiol (CBD) markets are set to grow exponentially over the next few years, with the cannabis sector set to rise over 2400% and CBD set to grow over 400% by 2023 (report by analytics and market research firm Brightfield Group).
Europe’s CBD market was estimated at $318m in 2018 and is tipped to rise to $416m in 2019, according to the report, entitled European CBD & Cannabis Market 2019 Report. CBD is then expected to grow to nearly $1.7bn by 2023.
The market is “poised to grow more quickly with both the likely blessing of global bodies such as the UN, and the European Union’s Novel Foods Act (health and safety regulations) eventually permitting for CBD to be sold like other ingestible products on the mainstream market,” Brightfield said in the report.
The Location: The Beja region of Portugal is deemed to have California based weather and one of the best climates globally for outdoor cannabis cultivation, situated around 45 minutes from the tourist coastal district the Algarve.
The site of total 105 hectares (1,005,000 m2) was carefully and strategically selected following extensive due diligence, land, security and environment assessments. The site sits within a valley, with only one entrance to the facility, with a 1-2km distance to the cultivation site, further enhancing the security risk impact.
Examples of application aeras for medical cannabis:
Dermatologhie: The anti-inflammatory properties of CBD can help to tackle skin issues such as eczema, seborrheic dermatitis and even dandruff! You’ll be amazed to discover the various benefits CBD can offer.
Anti-depressants: THC and CBD cannabinoids within medical cannabis can both act as excellent antidepressants. THC can bind to the same receptors as the brain’s natural anandamide, or “bliss molecule”, whilst CBD slows the brain’s breakdown of anandamide.
Multiple Sclerosis: According to a 2014 survey commissioned by the MS Society, one in five people with MS use cannabis to ease symptoms, including muscle spasms, stiffness and pain. We are only just beginning to unlock the potential of the cannabis plant, and it’s encouraging to see so much promising research in this area.
Cancer Therapy: Recent animal studies have suggested that cannabis extracts may help to kill certain cancer cells and reduce the size of others. Evidence from one cell culture study with rodents suggests that purified extracts from whole-plant cannabis can slow the growth of cancer cells for one of the most serious types of brain tumours.
Epilepsy: Amazing research published in The New England Journal of Medicine, reported a 41.9 % reduction in "drop seizures" using CBD, in patients with epilepsy.
Alzheimer: A 2006 study published in the journal, Molecular Pharmaceutics, suggested that medical cannabis can slow the progression of Alzheimer’s. The research found that THC can slow the formation of amyloid plaques, which are associated with this terrible disease, by blocking the enzyme in the brain that makes them. Cannabinoids can offer so many potential health.
Offering: Symtomax has now entered into its second round of funding as it enters into Phase II of the construction of the Production Facility and purchasing of equipment. Symtomax have created a debt based Loan Note offering of 12% in year 1 and 12% in year 2 paid annually, with a clear defined exit, based on 19.4 Million euros worth of product pre-orders in the form of an offtake agreement with just one reputable company and with many more under negotiation due to the lack of supply in the market.